Recruiting PHASE4 Schizophrenia and Related Disorders

New treatment option for Schizophrenia and Related Disorders

Official title "Extended" (Alternate Day) Antipsychotic Dosing

ClinicalTrials.gov ID: NCT04478838

What this study is testing

What is Risperidone?

Risperidone is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for schizophrenia and related disorders.

Also referred to as Risperdal.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment. It is also evaluating whether there may be differences in terms of side effects.
  • Phase 4: studies an already-approved treatment
  • Time commitment: about 1 year
  • You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • (i) A primary diagnosis of a Schizophrenia Spectrum or Other Psychotic Disorder as defined by the DSM-5 diagnosis and confirmed by the MINI (Version...
  • (ii) age 18 or older
  • (iii) female participants of childbearing potential must be using a reliable method of contraception and have a negative pregnancy test at the time...
  • (iv) ability to communicate in English
  • (v) capacity to provide written, informed consent, as assessed using the MacCAT-CR at time of consent

You likely can't join if

  • (i) exposure to a depot AP within 1 year (i.e., no depot AP injection within the last year)
  • (ii) Current diagnosis of substance use disorder according to DSM-5 criteria (verified through the MINI for Psychotic Disorders (Version 7.0.2) and a...
  • (iii) ECT within the last 3 months
  • (iv) pregnancy or lactation
  • (v) neurological condition (dementia including Alzheimer's disease, multiple sclerosis, epilepsy, stroke, or traumatic brain injury)
  • (vi) allergy to the study drugs and their excipients
See the full eligibility criteria
Who can join
  • (i) A primary diagnosis of a Schizophrenia Spectrum or Other Psychotic Disorder as defined by the DSM-5 diagnosis and confirmed by the MINI (Version 7.0.2)
  • (ii) age 18 or older
  • (iii) female participants of childbearing potential must be using a reliable method of contraception and have a negative pregnancy test at the time of enrolment and must, in the investigator's opinion, practice a...
  • (iv) ability to communicate in English
  • (v) capacity to provide written, informed consent, as assessed using the MacCAT-CR at time of consent
  • (vi) stabilized as outpatients with a single oral AP (risperidone or olanzapine or paliperidone\ ) at the same dose for ≥3 months i. On a prescribed risperidone dose of between 1-6mg, or a prescribed olanzapine dose of...
  • (vii) evidence of adherence with current AP treatment
What rules you out
  • (i) exposure to a depot AP within 1 year (i.e., no depot AP injection within the last year)
  • (ii) Current diagnosis of substance use disorder according to DSM-5 criteria (verified through the MINI for Psychotic Disorders (Version 7.0.2) and a positive drug screen for street and /or prescription drugs not...
  • (iii) ECT within the last 3 months
  • (iv) pregnancy or lactation
  • (v) neurological condition (dementia including Alzheimer's disease, multiple sclerosis, epilepsy, stroke, or traumatic brain injury)
  • (vi) allergy to the study drugs and their excipients
  • (vii) allergy (e.g., galactosaemia) or severe intolerance to lactose
  • (viii) negative urine drug screen result for Olanzapine or Risperidone or Paliperidone (if applicable)

The study team makes the final eligibility decision.

Where it's taking place

  • Toronto, Ontario, Canada

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The study runs about 1 year per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.